National Bank Of Canada Intellia Therapeutics, Inc. Transaction History

National Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$20.02 - $27.22 $10,010 - $13,610	500 Added 100.0%	1,000 $22,000
Q1 2024 May 13, 2024	BUY	$23.82 - $32.8 $11,314 - $15,579	475 Added 1900.0%	500 $13,000
Q3 2023 Oct 10, 2023	BUY	$31.62 - $45.78 $316 - $457	10 Added 66.67%	25 $0
Q4 2022 Jan 24, 2023	SELL	$33.21 - $62.69 $22,748 - $42,942	-685 Reduced 97.86%	15 $0
Q3 2022 Oct 13, 2022	BUY	$53.92 - $71.7 $37,744 - $50,190	700 New	700 $39,000
Q2 2022 Jul 28, 2022	SELL	$38.49 - $76.21 $9,199 - $18,214	-239 Closed	0 $0
Q1 2022 May 05, 2022	SELL	$58.27 - $118.99 $2,913 - $5,949	-50 Reduced 17.3%	239 $17,000
Q4 2021 Jan 24, 2022	BUY	$100.76 - $138.36 $29,119 - $39,986	289 New	289 $34,000

336

95.3M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $632M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.